Antibody Response to Pneumocystis jirovecii: Antibody Response to Pneumocystis jirovecii Major Surface Glycoprotein

We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Daly, Kieran R., Huang, Laurence, Morris, Alison, Koch, Judy, Crothers, Kristina, Levin, Linda, Eiser, Shary, Satwah, Supriya, Zucchi, Patrizia, Walzer, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291227/
https://www.ncbi.nlm.nih.gov/pubmed/16965702
http://dx.doi.org/10.3201/eid1208.060230
Descripción
Sumario:We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3–4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count >50 cells/μL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies.

Ejemplares similares